See more : KIYO Learning Co.,Ltd. (7353.T) Income Statement Analysis – Financial Results
Complete financial analysis of Sun Pharma Advanced Research Company Limited (SPARC.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sun Pharma Advanced Research Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Teikoku Electric Mfg.Co.,Ltd. (TKOLF) Income Statement Analysis – Financial Results
- China Yanyuan Yuhui Natl Ed Group Inc. (YYYH) Income Statement Analysis – Financial Results
- The Lexington Company AB (publ) (LEX.ST) Income Statement Analysis – Financial Results
- B. Riley Financial, Inc. 6.00% Senior Notes Due 2028 (RILYT) Income Statement Analysis – Financial Results
- MODI’S NAVNIRMAN LIMITED (MODIS.BO) Income Statement Analysis – Financial Results
Sun Pharma Advanced Research Company Limited (SPARC.BO)
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. The company was incorporated in 2006 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755.45M | 2.39B | 1.37B | 2.53B | 768.14M | 1.83B | 782.59M | 1.81B | 1.61B | 1.56B | 1.67B | 872.79M | 289.77M | 583.48M | 342.97M | 351.42M | 374.63M | 0.00 | 0.00 |
| Cost of Revenue | 1.36B | 1.72B | 1.27B | 2.02B | 1.93B | 1.60B | 1.44B | 1.62B | 1.38B | 1.21B | 607.45M | 93.05M | 74.16M | 76.82M | 67.63M | 75.60M | 68.62M | 3.10M | 0.00 |
| Gross Profit | -602.41M | 672.00M | 105.52M | 507.62M | -1.16B | 224.42M | -659.10M | 192.30M | 228.69M | 345.94M | 1.06B | 779.74M | 215.61M | 506.66M | 275.35M | 275.82M | 306.01M | -3.10M | 0.00 |
| Gross Profit Ratio | -79.74% | 28.14% | 7.69% | 20.07% | -151.07% | 12.27% | -84.22% | 10.62% | 14.18% | 22.21% | 63.63% | 89.34% | 74.41% | 86.83% | 80.28% | 78.49% | 81.68% | 0.00% | 0.00% |
| Research & Development | 0.00 | 4.53B | 3.24B | 3.88B | 3.87B | 1.48B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.54B | 1.33B | 695.23M | 561.41M | 442.90M | 560.33M | 484.28M | 264.46M | 35.58M | 23.28M | 10.05M | 418.49M | 472.74M | 194.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.54B | 1.33B | 695.23M | 561.41M | 442.90M | 560.33M | 484.28M | 264.46M | 35.58M | 23.28M | 10.05M | 418.49M | 472.74M | 194.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -2.15B | 168.00K | 771.00K | 4.71M | 310.00K | 9.31M | 117.00K | 123.00K | 18.74M | -2.28M | -2.18M | -2.78M | 4.00K | 3.00K | 0.00 | 0.00 | 649.00K | 41.00K | 0.00 |
| Operating Expenses | -602.41M | 2.91B | 2.07B | 1.97B | 1.99B | 1.75B | 1.85B | 1.50B | 930.17M | 765.26M | 760.69M | 976.59M | 946.39M | 602.81M | 489.03M | 395.88M | 351.49M | 15.28M | 0.00 |
| Cost & Expenses | 4.87B | 4.62B | 3.33B | 3.99B | 3.92B | 3.35B | 3.29B | 3.12B | 2.31B | 1.98B | 1.37B | 1.07B | 1.02B | 679.63M | 556.66M | 471.48M | 420.11M | 18.38M | 0.00 |
| Interest Income | 254.76M | 75.95M | 14.10M | 8.97M | 29.32M | 31.36M | 6.36M | 116.47M | 7.32M | 27.59M | 39.00M | 7.19M | 5.77M | 3.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.90M | 76.35M | 133.29M | 106.50M | 26.75M | 939.00K | 1.23M | 18.20M | 21.45M | 2.18M | 55.97M | 39.50M | 2.75M | 1.27M | 1.75M | 2.43M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 125.11M | 117.71M | 101.62M | 109.23M | 94.81M | 75.52M | 81.85M | 82.40M | 75.79M | 72.40M | 35.72M | 33.96M | 31.62M | 29.86M | 25.99M | 18.36M | 12.67M | 1.00M | 0.00 |
| EBITDA | -3.73B | -2.03B | -1.80B | -1.30B | -3.00B | -1.38B | -1.89B | -1.09B | -599.78M | -317.84M | 437.72M | -148.70M | -687.95M | -53.94M | -187.70M | -101.70M | -32.81M | -17.35M | 0.00 |
| EBITDA Ratio | -493.91% | -86.41% | -134.98% | -51.63% | -399.73% | -79.36% | -309.00% | -60.25% | -37.32% | -20.72% | 23.27% | -18.39% | -237.46% | -9.36% | -54.73% | -28.94% | -8.76% | 0.00% | 0.00% |
| Operating Income | -4.12B | -2.24B | -1.96B | -1.46B | -3.15B | -1.52B | -2.51B | -1.31B | -704.26M | -395.02M | 353.03M | -194.42M | -719.69M | -84.46M | -213.69M | -120.06M | -45.48M | -18.38M | 0.00 |
| Operating Income Ratio | -544.71% | -93.66% | -142.86% | -57.60% | -410.02% | -83.18% | -320.44% | -72.24% | -43.67% | -25.36% | 21.14% | -22.28% | -248.37% | -14.47% | -62.30% | -34.16% | -12.14% | 0.00% | 0.00% |
| Total Other Income/Expenses | 246.72M | 10.61M | -73.23M | -54.37M | 25.51M | 66.87M | 537.77M | 117.35M | 1.55M | -184.00K | -9.79M | -30.53M | 8.46M | 11.08M | -1.75M | -4.85M | -135.00K | 50.00K | 0.00 |
| Income Before Tax | -3.87B | -2.23B | -2.03B | -1.51B | -3.12B | -1.45B | -1.97B | -1.19B | -699.92M | -395.20M | 343.24M | -224.95M | -722.32M | -85.08M | -215.44M | -124.91M | -45.62M | -18.34M | 0.00 |
| Income Before Tax Ratio | -512.05% | -93.22% | -148.19% | -59.75% | -406.70% | -79.53% | -251.73% | -65.76% | -43.40% | -25.38% | 20.55% | -25.77% | -249.28% | -14.58% | -62.81% | -35.55% | -12.18% | 0.00% | 0.00% |
| Income Tax Expense | 3.82M | -20.52M | -7.62M | 32.86M | -45.06M | -36.97M | 1.33M | 18.25M | 19.31M | 0.00 | 40.00M | 0.00 | 0.00 | -69.00K | 96.00K | 158.42M | 3.21M | 31.50M | 0.00 |
| Net Income | -3.87B | -2.23B | -2.03B | -1.51B | -3.12B | -1.45B | -1.97B | -1.19B | -699.92M | -395.20M | 303.24M | -224.95M | -722.32M | -85.01M | -215.53M | -91.41M | -48.83M | -49.84M | 0.00 |
| Net Income Ratio | -512.56% | -93.22% | -148.19% | -59.75% | -406.70% | -79.53% | -251.73% | -65.76% | -43.40% | -25.38% | 18.15% | -25.77% | -249.28% | -14.57% | -62.84% | -26.01% | -13.03% | 0.00% | 0.00% |
| EPS | -11.93 | -7.82 | -7.73 | -5.77 | -11.92 | -5.69 | -7.94 | -4.84 | -2.96 | -1.67 | 1.27 | -1.03 | -3.41 | -0.40 | -1.02 | -0.43 | -0.24 | -0.24 | -0.76 |
| EPS Diluted | -11.93 | -7.82 | -7.73 | -5.77 | -11.92 | -5.69 | -7.94 | -4.84 | -2.96 | -1.67 | 1.27 | -1.03 | -3.41 | -0.40 | -1.02 | -0.43 | -0.23 | -0.24 | -0.76 |
| Weighted Avg Shares Out | 324.57M | 284.70M | 263.14M | 262.05M | 262.05M | 255.60M | 248.08M | 246.17M | 236.69M | 236.68M | 238.28M | 219.41M | 211.96M | 212.02M | 212.02M | 212.02M | 203.88M | 212.02M | 43.47K |
| Weighted Avg Shares Out (Dil) | 324.57M | 284.70M | 263.14M | 262.05M | 262.05M | 255.60M | 248.08M | 246.17M | 236.69M | 236.68M | 238.28M | 219.41M | 211.96M | 212.02M | 212.02M | 212.02M | 212.02M | 212.02M | 43.47K |
Source: https://incomestatements.info
Category: Stock Reports